Trevi Therapeutics (TRVI) Total Non-Current Liabilities (2018 - 2022)

Trevi Therapeutics' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $15.6 million for Q4 2022.

• On a quarterly basis, Total Non-Current Liabilities fell 26.93% year-over-year to $15.6 million in Q4 2022; TTM through Dec 2022 was $15.6 million, a 26.93% decrease from a year earlier, with the FY2022 full-year figure at $15.6 million, down 26.93% from the prior year.
• Total Non-Current Liabilities retreated to $15.6 million in Q4 2022 per TRVI's latest filing, from $18.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $55.7 million in Q3 2020 and bottomed at $9.4 million in Q4 2018.
• The 4-year median for Total Non-Current Liabilities is $19.8 million (2022), against an average of $21.9 million.
• Biggest YoY gain for Total Non-Current Liabilities was 8.31% in 2021; the steepest drop was 64.0% in 2021.
• Year by year, Total Non-Current Liabilities stood at $9.4 million in 2018, then soared by 108.41% to $19.7 million in 2020, then advanced by 8.31% to $21.3 million in 2021, then slipped by 26.93% to $15.6 million in 2022.
• Per Business Quant, the three latest TRVI Total Non-Current Liabilities figures stand at $15.6 million (Q4 2022), $18.4 million (Q3 2022), and $20.9 million (Q2 2022).